2020
Chapter 11 Trials and tribulations: Clinical trials and the future
Khanna S, Burtness B. Chapter 11 Trials and tribulations: Clinical trials and the future. 2020, 197-215. DOI: 10.1016/b978-0-12-820679-9.00011-6.Peer-Reviewed Original ResearchClinical trialsNeck cancerRecent landmark trialsRole of immunotherapyRisk stratification toolPromising clinical trialsMetastatic headPoor accrualSystemic treatmentLandmark trialsNeck specialistsStratification toolDedicated headTrialsCurrent standardCancerExciting advancesLack of fundingHeadImmunotherapyHPVHNSCCTherapyDiseasePathobiology
2017
Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer
Biktasova A, Hajek M, Sewell A, Gary C, Bellinger G, Deshpande HA, Bhatia A, Burtness B, Judson B, Mehra S, Yarbrough WG, Issaeva N. Demethylation Therapy as a Targeted Treatment for Human Papillomavirus–Associated Head and Neck Cancer. Clinical Cancer Research 2017, 23: 7276-7287. PMID: 28916527, DOI: 10.1158/1078-0432.ccr-17-1438.Peer-Reviewed Original ResearchConceptsClinical trialsHNSCC cellsMatrix metalloproteinasesHuman papillomavirus-associated headNeck squamous cell carcinomaSquamous cell carcinomaAbility of HPVClin Cancer ResTumor cell proliferationNeck cancer cellsWindow trialsCell carcinomaEffective therapyPreclinical modelsHPVHPV oncogenesMouse modelMouse blood vesselsDNA demethylating agentHNSCCXenografted tumorsHPV genesIFN responseTherapyTumor samples
2014
A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer.
Seiwert T, Burtness B, Weiss J, Gluck I, Eder J, Pai S, Dolled-Filhart M, Emancipator K, Pathiraja K, Gause C, Iannone R, Brown H, Houp J, Cheng J, Chow L. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancer. Journal Of Clinical Oncology 2014, 32: 6011-6011. DOI: 10.1200/jco.2014.32.15_suppl.6011.Peer-Reviewed Original Research
2013
Psychosocial functioning and vascular endothelial growth factor in patients with head and neck cancer
Fang CY, Egleston BL, Ridge JA, Lango MN, Bovbjerg DH, Studts JL, Burtness BA, Einarson MB, Klein–Szanto A. Psychosocial functioning and vascular endothelial growth factor in patients with head and neck cancer. Head & Neck 2013, 36: 1113-1119. PMID: 23804308, PMCID: PMC4099415, DOI: 10.1002/hed.23421.Peer-Reviewed Original ResearchConceptsVascular endothelial growth factorEndothelial growth factorPsychosocial functioningVEGF expressionNeck squamous cell carcinomaGrowth factorSquamous cell carcinomaTumor VEGF expressionGreater VEGF expressionHPV statusPoor outcomeCell carcinomaPatient populationPoor prognosisDisease stageHuman papillomavirusNeck cancerBiobehavioral pathwaysPatientsHPVTumor samplesVEGF analysisHNSCCsPrognosisSurgery
2008
Oropharyngeal cancer.
Psyrri A, Prezas L, Burtness B. Oropharyngeal cancer. Clinical Advances In Hematology And Oncology 2008, 6: 604-12. PMID: 18820604.Peer-Reviewed Original ResearchConceptsOropharyngeal squamous cell carcinomaMolecular pathogenesisHigh-risk human papillomavirus (HPV) typesSquamous cell carcinomaHuman papillomavirus typesTerms of etiologySquamous histologyClinical presentationCell carcinomaClinical behaviorPapillomavirus typesType 16Significant heterogeneityCarcinomaPathogenesisHPVOropharynxEtiologyTherapyHistologyInfectionEpidemiologyDiagnosis